ライフサイエンスコーパス: von Willebrand factor

1 4, CD45) and endothelial markers (CD31, vWf, von Willebrand factor).

2 ts only at the ABO locus for factor VIII and von Willebrand factor.

3 on in controls, most notably factor VIII and von Willebrand factor.

4 the AP, and the release of the prothrombotic von Willebrand factor.

5 glycation end products (3.5 [1.7-7.2]), and von Willebrand Factor (3.1 [2.0-5.2]).

6 With a von Willebrand factor A (VWA) domain and six thrombospon

7 ly of B. burgdorferi proteins containing the von Willebrand factor A (vWFA) domain.

8 ific humoral autoimmune response against the von Willebrand factor A domain-containing protein 5a, an

9 racting with AAA+ ATPase (ViaA) containing a von Willebrand Factor A domain.

10 This mechanism may apply to other von Willebrand factor A domains undergoing large conform

11 haI domains of integrin are the best-studied von Willebrand factor A domains undergoing significant c

12 e the noncollagenous domain 1, including the von Willebrand factor A-like domain 2 (vWFA2).

13 lost for alpha2delta-1 with mutations in the von-Willebrand-factor-A domain.

14 tein Ib-IX complex, which binds to plasmatic von Willebrand factor adsorbed on laminins.

15 With the exception of von Willebrand factor, all the above changes correlated

16 a/SU5416 mouse model identified the presence von Willebrand factor/alpha-smooth muscle actin-positive

17 Von Willebrand factor, an ultralarge concatemeric blood

18 Increase in fibrinogen, factor VIII, and von Willebrand factor and decrease in antithrombin III c

19 Patients with severe CAV had raised serum von Willebrand factor and decreased serum thrombomodulin

20 eas vWbp has been reported to associate with von Willebrand factor and fibrinogen.

21 ody KM33 but retained substantial binding to von Willebrand factor and LRP.

22 rotein expression of the endothelial markers von Willebrand factor and neuregulin-1, or phosphorylati

23 % was observed in the alpha-granule proteins von Willebrand factor and P-selectin.

24 histamine-evoked secretion of the WPB cargos von Willebrand factor and P-selectin.

25 Willebrand factor-platelet strings (on both von Willebrand factor and platelets) and on endothelial

26 growth of microthrombi that are composed of von Willebrand factor and platelets, which account for t

27 Basal plasma levels of von Willebrand factor and recruitment of platelets to th

28 ich remain anchored to the vascular wall via von Willebrand factor and reveal significant neutrophil

29 ogenic mimicry (VM), the mature vasculature (von Willebrand Factor) and tumor induced angiogenesis (b

30 of GPIbalpha, impaired platelet adhesion to von Willebrand factor, and inability to form stable thro

31 tiple constituents, including phospholipids, von Willebrand factor, and low-density lipoprotein recep

32 g in affinity, dependence on separation from von Willebrand factor, and mediation by the C2 domain.

33 ndothelial injury, including angiopoietin-2, von Willebrand Factor, and soluble thrombomodulin.

34 ant cell arteritis and Takayasu's arteritis; von Willebrand factor antigen in childhood central nervo

35 sed postoperative portal venous pressure and von Willebrand factor antigen levels as a marker for int

36 Von Willebrand factor antigen-positive vasculature displ

37 With the exception of von Willebrand factor, assessed with the median cutoff m

38 Adjustment for factor VIII or von Willebrand factor attenuated these odds ratios, indi

39 Fn deposition was independent of fibrinogen, von Willebrand factor, beta3 integrin, and platelets.

40 inants (IsdA and IsdB), coagulase (Coa), and von Willebrand factor binding protein (vWbp)-are dispens

41 ach assigns this association to the ADAMTS13 von Willebrand factor-binding domain (P=1.2x10(-4)).

42 lococcus aureus secretes coagulase (Coa) and von Willebrand factor-binding protein (vWbp) to activate

43 ecretes the coagulases staphylocoagulase and von Willebrand factor-binding protein, both of which for

44 ve protein) and endothelial cell activation (von Willebrand factor) both at baseline and during follo

45 ns in D-dimer by 24% (95% CI, -30% to -18%), von Willebrand factor by 22% (95% CI, -35% to -9%), thro

46 extracellular proteins, among which are many von Willebrand factor C (vWC) domain-containing proteins

47 th factors bind to both an N- and C-terminal von Willebrand factor C domain of chordin.

48 d by the co-injection of mRNA coding for the von Willebrand factor C domain of collagen IIalpha1a, in

49 lial cell and junctional proteins, including von Willebrand factor, CD31, occludin, and vascular endo

50 din type 1 repeats, member 13), the specific von Willebrand factor-cleaving protease.

51 r, we focus on emerging data suggesting that von Willebrand factor, coagulation cascade activation, a

52 c activity after 6 wk of treatment and lower von Willebrand factor concentrations in both Arg16/Gln27

53 ogen, tissue necrosis factor-a, sE-selectin, von Willebrand factors, d-dimers, matrix metalloproteina

54 of high molecular weight (HMW) multimers of von Willebrand factor defect could be instantaneous afte

55 th microbubbles targeted to the A1 domain of von Willebrand factor demonstrated selective signal enha

56 As both integrins and MUC5AC have a von Willebrand factor domain, we assessed for possible i

57 in synaptogenic domain and the alpha2delta-1 von-Willebrand-factor domain.

58 ging, we simultaneously monitored reversible Von Willebrand factor extension and binding to GPIbalpha

59 Replacement therapy with plasma-derived von Willebrand factor-factor VIII concentrates represent

60 y components of the thrombus itself, such as von Willebrand factor, fibrinogen, and thrombocytes.

61 d with plasma-derived factor VIII containing von Willebrand factor had a lower incidence of inhibitor

62 Caplacizumab, an anti-von Willebrand factor humanized single-variable-domain i

63 The content of von Willebrand factor in the products and switching amon

64 of inhibitor development, and the content of von Willebrand factor in the products and switching amon

65 ogether with that of the endothelial marker, von Willebrand factor, in human and rat liver tissue, at

66 tissue inhibitor of metalloproteinase 2, and von Willebrand factor-in plasma samples from 611 patient

67 of the vasopressin type 2 receptor-mediated von Willebrand factor increase by arginine vasopressin a

68 ge and apoptosis (release of fractalkine and von Willebrand factor; increased caspase 3 expression).

69 Re-compaction of Von Willebrand factor is accelerated by intramolecular i

70 We show that Von Willebrand factor is activated through a two-step co

71 Because von Willebrand factor is involved in coagulatory and inf

72 Von Willebrand factor is proposed to be mechanically act

73 teractions are in part caused by endothelial von Willebrand factor large multimers, which can be reve

74 L for the <1st eGFR percentile category) and von Willebrand factor levels (adjusted mean difference,

75 risk via concurrently raised factor VIII and von Willebrand factor levels.

76 istal tubular cytokeratin 7, and endothelial von Willebrand factor markers.

77 subjects was analyzed by ELISAs for soluble von Willebrand factor mature protein (VWF:Ag) and propep

78 ding apolipoprotein A-I, thrombomodulin, and von Willebrand factor, may contribute to vascular diseas

79 recombinant ADAMTS13 eliminated platelet and von Willebrand factor molecular imaging signal.

80 These results demonstrate that variations in von Willebrand factor multimeric pattern are highly dyna

81 cy-associated peptide, TGF-beta1, clusterin, von Willebrand factor, multimerin-1, protein disulfide i

82 inhibits the interaction between ultralarge von Willebrand factor multimers and platelets.

83 ts, no aHUS patients demonstrated ultralarge von Willebrand factor multimers at presentation.

84 ecreased proportion of high-molecular-weight von Willebrand factor multimers could reduce platelet ad

85 von Willebrand factor multimers were abnormal in 1 of 26

86 against ADAMTS13 prohibit the processing of von Willebrand factor multimers, initiating a rare and l

87 13 variant eliminated circulating ultralarge von Willebrand factor multimers, prevented severe thromb

88 ample for such a key component as it cleaves von Willebrand factor multimers, reduces platelet adhesi

89 ed by aggregation of platelets on ultralarge von Willebrand factor multimers.

90 Further studies demonstrated that neither von Willebrand factor nor platelet glycoprotein Ib-alpha

91 in high-molecular-weight (HMW) multimers of von Willebrand factor or point-of-care assessment of hem

92 d with plasma-derived factor VIII containing von Willebrand factor or recombinant factor VIII.

93 r with its binding to phospholipid surfaces, von Willebrand factor, or other components of the intrin

94 47)), and rs505922 in the ABO gene with both von Willebrand factor (p = 4.7 x 10(-57)) and factor VII

95 teractions, increased endothelial-associated von Willebrand factor, particularly in a multimerized fo

96 Unlike von Willebrand factor, plasma angiopoietin-2 has differe

97 EDE levels of VCAM-1, von Willebrand factor, platelet-derived growth factor (P

98 ystem, under shear, induced C3 deposition on von Willebrand factor-platelet strings (on both von Will

99 latelet buds containing incorrect numbers of von Willebrand factor-positive granules.

100 therlands (WiN) study by using the ratios of von Willebrand factor propeptide (VWFpp) or factor VIII

101 The ratios between von Willebrand factor propeptide (VWFpp) or factor VIII

102 ives a hybrid molecule of FVIII fused to the von Willebrand Factor propeptide-D2 domain that traffics

103 otein-cleaving enzymes (ADAMTS7 and 12), the von-Willebrand Factor proteinase (ADAMTS13) and a group

104 -0.3, P < 0.01) or endothelial injury marker von Willebrand factor (R = +0.3; P < 0.01).

105 e Neu3 that remove sialic acid from platelet von Willebrand factor receptor (VWFR), specifically the

106 ceptor complex GPVI-FcR gamma-chain, and the von Willebrand factor receptor complex GPIb-IX-V, which

107 ollagen-binding integrin alpha2beta1 and the von Willebrand factor receptor GPIb.

108 thrombospondin motifs 13 (ADAMTS13) cleaves von Willebrand factor, reducing its prothrombotic activi

109 was deposited diffusely on capillaries, and von Willebrand factor released from endothelial cells co

110 with proliferating cell nuclear antigen and Von Willebrand factor revealed delayed and/or diminished

111 eron-Gamma Induced Protein 10[rs4256246] and von-Willebrand-Factor[rs12829220] in the control group;

112 ety and pharmacokinetics (PK) of recombinant von Willebrand factor (rVWF) combined at a fixed ratio w

113 hase 3 clinical trial evaluating recombinant von Willebrand factor (rVWF) for the treatment of hemorr

114 ety and hemostatic efficacy of a recombinant von Willebrand factor (rVWF) for treatment of bleeds in

115 Intragraft deposition of C4d, von Willebrand factor, SAP, and activated caspase 3 was

116 and diastolic blood pressures), hemostasis (von Willebrand factor, soluble CD40 ligand, and P-select

117 a wide range of qualitative abnormalities of von Willebrand factor structure and function resulting i

118 reatment with carvedilol resulted in a lower von Willebrand factor than did metoprolol (149% +/- 13%

119 blast growth factor-2), thrombosis (D-dimer, von Willebrand factor, thrombin-antithrombin III), infla

120 Here we demonstrate that the von Willebrand factor type A (VWA) domain within the cle

121 aining domains of carbonic anhydrase, Sushi, Von Willebrand factor type A, and chitin binding, were i

122 ke growth factor-binding protein (IGFBP) and von Willebrand factor type C (vWC) domains.

123 well as secreting and anchoring ultra-large von Willebrand factor (ULVWF) multimers in long string-l

124 95% attachment of the S aureus by ultralarge von Willebrand factor (ULVWF).

125 here was less adhesion of human platelets to von Willebrand factor under high shear conditions after

126 Here we show that binding of its ligand, von Willebrand factor, under physiological shear stress

127 pression of endothelial cell genes including von Willebrand factor, VE-cadherin, and eNOS were observ

128 The von Willebrand factor (VWF) A1 and A3 domains are struct

129 ecently reported a sequence variation in the von Willebrand factor (VWF) A1 domain, p.D1472H (D1472H)

130 d trigger a conformational transition in the von Willebrand factor (VWF) A2 domain, from its native f

131 Rare missense mutations in the von Willebrand factor (VWF) A3 domain that disrupt colla

132 Limited data suggest that von Willebrand factor (VWF) abnormalities may accompany

133 New options for laboratory assessment of von Willebrand factor (VWF) activity include a new plate

134 ity of 16%, factor IX (FIX) activity of 74%, von Willebrand factor (VWF) activity of 12%, VWF antigen

135 We discovered that von Willebrand factor (VWF) acts as a cofactor for facto

136 Von Willebrand factor (vWF) adsorbs and immobilizes plat

137 he liver, and its main function is to cleave von Willebrand factor (VWF) anchored on the endothelial

138 (WPBs), which contain the hemostatic protein von Willebrand factor (VWF) and a cocktail of angiogenic

139 VAD support causes pathologic degradation of von Willebrand factor (vWF) and bleeding from gastrointe

140 of these and other VWF coding variants with von Willebrand factor (VWF) and factor VIII (FVIII) leve

141 nctionality of the platelet-adhesive protein von Willebrand factor (VWF) and its cleaving protease AD

142 We identify reduced plasma levels of von Willebrand factor (VWF) and reduced VWF synthesis, s

143 ECs synthesize both the clotting initiator von Willebrand factor (VWF) and the complement regulator

144 ow through its binding to the plasma protein von Willebrand factor (VWF) and transmits a signal into

145 To evaluate vascular cells, von Willebrand factor (vWF) and vascular endothelial gro

146 e (AVWS) secondary to a nonneutralizing anti-von Willebrand factor (VWF) antibody associated with an

147 derate bleeding symptoms associated with low von Willebrand factor (VWF) antigen levels, decreased co

148 ion coefficient adjusted for log age and log von Willebrand factor (VWF) antigen was -0.32 (P = .004)

149 The patients' sera were tested for von Willebrand factor (VWF) antigen, VWF collagen-bindin

150 tween collagenous extracellular matrices and von Willebrand factor (VWF) are critical for hemostasis

151 t the terminal glycan structures of platelet von Willebrand factor (VWF) are markedly different compa

152 on by increased accumulation and activity of von Willebrand factor (vWF) at poststenotic sites.

153 ified that bind to putative phospholipid and von Willebrand factor (VWF) binding epitopes and block e

154 unrecognized consequence of variant type 2B von Willebrand factor (vWF) binding to blood platelets.

155 arly stage of hemostasis and thrombosis: the von Willebrand factor (VWF) binding to platelet glycopro

156 neutrophils inhibit proteolytic cleavage of von Willebrand factor (VWF) by ADAMTS13 in a concentrati

157 of the multimeric blood coagulation protein von Willebrand Factor (VWF) by ADAMTS13 is crucial for p

158 Mutations in the ultralong vascular protein von Willebrand factor (VWF) cause the common human bleed

159 the platelet GPIbalpha adhesive A1 domain of von Willebrand factor (VWF) causes quantitative VWF defi

160 Plasma factor VIII (FVIII) and von Willebrand factor (VWF) circulate together as a comp

161 Enhanced von Willebrand factor (VWF) clearance is important in th

162 loss of terminal sialic acid causes enhanced von Willebrand factor (VWF) clearance through the Ashwel

163 It is characterized by a deficiency of the von Willebrand factor (VWF) cleaving enzyme, ADAMTS13 (a

164 Von Willebrand factor (VWF) contains binding sites for p

165 Binding to the von Willebrand factor (VWF) D'D3 domains protects factor

166 The plasma glycoprotein von Willebrand factor (VWF) exhibits fivefold antigen le

167 iR-24), through which hyperglycemia augments von Willebrand factor (VWF) expression and secretion.

168 drophobic pocket in the central A2 domain of von Willebrand factor (VWF) for its proteolysis.

169 re specific cigar-shaped granules that store von Willebrand factor (VWF) for its regulated secretion

170 d that expression or infusion of a truncated von Willebrand factor (VWF) fragment containing the fact

171 Endothelial secretion of von Willebrand factor (VWF) from intracellular organelle

172 pe through JAK2V617F-regulated inhibition of von Willebrand factor (VWF) function and/or secretion.

173 DAMTS13) is a metalloprotease that regulates von Willebrand factor (VWF) function.

174 The primary hemostatic von Willebrand factor (vWF) functions to sequester plate

175 ng of the first intronic sequence within the von Willebrand factor (vWF) gene facilitates expression

176 ilent mutation, c.7464C>T, in exon 44 of the von Willebrand factor (VWF) gene in a family with type 1

177 Approximately 10% of von Willebrand factor (VWF) gene mutations are thought t

178 heterozygous for a missense mutation in the von Willebrand factor (VWF) gene.

179 von Willebrand factor (VWF) has been considered as a mar

180 Although much of the function of von Willebrand factor (VWF) has been revealed, detailed

181 An elevated level of von Willebrand factor (VWF) in diabetic patients is asso

182 M) has been associated with plasma levels of von Willebrand factor (VWF) in healthy individuals.

183 nt data showing the role of platelet-derived von Willebrand factor (VWF) in mediating ischemic stroke

184 antithrombotic properties because it cleaves von Willebrand factor (VWF) in smaller, less active mult

185 otein (GP) Ib-IX-V complex, which recognizes von Willebrand factor (VWF) in the matrix.

186 gan et al have extended our understanding of von Willebrand factor (VWF) in the pathogenesis of malar

187 ke patients and found a distinct presence of von Willebrand factor (VWF) in various samples.

188 platelet glycoprotein Ibalpha (GPIbalpha) to von Willebrand factor (VWF) initiates platelet adhesion

189 Platelet-von Willebrand factor (VWF) interactions must be tightly

190 the arterial lumen is mediated by GpIbalpha-von Willebrand Factor (VWF) interactions.

191 Von Willebrand factor (vWF) is a biomarker of endothelia

192 echano-regulation of receptor-ligand binding.Von Willebrand factor (VWF) is a blood protein involved

193 The large multimeric glyocoprotein von Willebrand factor (VWF) is a crucial component of bo

194 Von Willebrand factor (VWF) is a key hemostatic protein

195 von Willebrand factor (VWF) is a large multimeric glycop

196 Von Willebrand factor (VWF) is a large, multimeric plasm

197 Von Willebrand factor (VWF) is a multimeric plasma glyco

198 Von Willebrand Factor (VWF) is a multimeric protein cruc

199 von Willebrand factor (VWF) is a particularly intriguing

200 von Willebrand factor (VWF) is amongst others synthesize

201 von Willebrand Factor (VWF) is an ultralong, concatameri

202 Activation by elongational flow of von Willebrand factor (VWF) is critical for primary hemo

203 The plasma protein von Willebrand factor (VWF) is essential for hemostasis

204 nd the release of the procoagulatory protein von Willebrand factor (VWF) is essential for malignancy,

205 Multimeric von Willebrand factor (VWF) is essential for primary hem

206 between coagulation factor VIII (FVIII) and von Willebrand factor (VWF) is of critical importance to

207 onstrated that the first intron of the human von Willebrand factor (vWF) is required for gene express

208 Platelet-von Willebrand factor (VWF) is stored within alpha-granu

209 von Willebrand factor (VWF) laboratory testing and full-

210 es against complement C1q (Fab anti-C1q) and von Willebrand factor (VWF) led us to investigate a pote

211 iagnosis and management of patients with low von Willebrand factor (VWF) levels (30-50 IU/dL).

212 ated with an early marked increase in plasma von Willebrand factor (VWF) levels, together with a path

213 We investigated whether platelets and von Willebrand factor (VWF) mediate bacterial adhesion t

214 -terminal cystine knot (CK) (CTCK) domain in von Willebrand factor (VWF) mediates dimerization of pro

215 The blood von Willebrand factor (VWF) mediates platelet adhesion t

216 or glycoprotein Ibalpha and the A1 domain of von Willebrand factor (VWF) mediates tethering/transloca

217 Von Willebrand factor (VWF) multimer size is controlled

218 ember 13) proteolysis of highly thrombogenic von Willebrand factor (VWF) multimers may accelerate ren

219 -linking during arterial thrombosis involves von Willebrand Factor (VWF) multimers.

220 to signal as they tether and translocate on von Willebrand factor (VWF) of injured arterial surfaces

221 II), and factor VIII (FVIII) and its carrier von Willebrand factor (vWF) play key roles in hemostasis

222 Von Willebrand factor (VWF) plays a central role in hemo

223 The large multimeric glycoprotein von Willebrand Factor (VWF) plays a pivotal adhesive rol

224 sease (VWD) have a qualitative defect of the von Willebrand factor (VWF) protein activities.

225 In most patients, the von Willebrand factor (VWF) rapidly loses large multimer

226 t in platelet activation induced through the von Willebrand Factor (VWF) receptor, the glycoprotein I

227 The development of alloantibodies against von Willebrand factor (VWF) represents a rare but seriou

228 von Willebrand factor (vWF) secretion by endothelial cel

229 ecular techniques to dissect a mechanism for von Willebrand factor (vWF) secretion from endothelial c

230 nstrate in vitro and in an animal model that von Willebrand factor (VWF) self-association under shear

231 The large plasma glycoprotein von Willebrand factor (VWF) senses hydrodynamic forces i

232 Association with the D'D3 domain of von Willebrand factor (VWF) stabilizes factor VIII (FVII

233 von Willebrand factor (VWF) strings are removed from the

234 The von Willebrand factor (VWF) synthesized and secreted by

235 LX-0081, a Nanobody against the A1 domain of von Willebrand factor (VWF) that blocks VWF binding to G

236 aracterized by gain-of-function mutations in von Willebrand factor (vWF) that enhance its binding to

237 ding is the capacity of endothelial-secreted von Willebrand factor (VWF) to assemble into thick bundl

238 The ability of von Willebrand factor (VWF) to initiate platelet adhesio

239 zed by mutations causing enhanced binding of von Willebrand factor (VWF) to platelets.

240 factor XIII (FXIIIa) covalently cross-links von Willebrand factor (VWF) to polymerizing fibrin.

241 inase that cleaves large multimeric forms of von Willebrand factor (VWF) to smaller, less adhesive fo

242 d strongly affects firm platelet adhesion on von Willebrand factor (VWF) under arterial flow.

243 heological shear forces in the blood trigger von Willebrand factor (VWF) unfolding which exposes the

244 Binding to von Willebrand factor (VWF) was maintained for all conju

245 els with von Willebrand disease pigs, plasma von Willebrand factor (vWF) was significantly increased

246 inogen activator (t-PA) antigen, D-dimer and von Willebrand factor (VWF) with coronary heart disease

247 The metalloprotease ADAMTS13 cleaves von Willebrand factor (VWF) within endovascular platelet

248 es progressed through Rab4(+), Rab11(+), and von Willebrand factor (VWF)(+) compartments in wild-type

249 Endothelial cells store von Willebrand Factor (vWF), a glycoprotein essential to

250 ponse, which in gnathostomes is regulated by von Willebrand factor (VWF), a glycoprotein that mediate

251 coagulability by affecting the production of von Willebrand factor (vWF), a key initiator of the clot

252 Von Willebrand factor (VWF), a key player in hemostasis,

253 We therefore aimed to assess von Willebrand factor (vWF), a marker of endothelial dam

254 investigated the interaction between Stx and von Willebrand Factor (VWF), a multimeric plasma glycopr

255 von Willebrand factor (VWF), a multimeric protein with a

256 y blockade of adhesion molecules P-selectin, von Willebrand factor (VWF), E-selectin, vascular cell a

257 We assessed von Willebrand factor (VWF), factor VIII, platelet activ

258 type I enhancer binding protein 1 (HIVEP1), von Willebrand factor (VWF), glutathione peroxidase 3 (G

259 e show that the endothelial-restricted gene, von Willebrand factor (VWF), is expressed in a mosaic pa

260 It's major component, the hemostatic protein von Willebrand factor (VWF), is known to assemble into l

261 binant human ADAMTS13 (rhADAMTS13), cleaving von Willebrand factor (VWF), reduces leukocyte recruitme

262 TS13 regulates blood coagulation by cleaving von Willebrand factor (VWF), reducing its procoagulant a

263 Unusually large von Willebrand factor (VWF), the first responder to vasc

264 ain the size of nanostructures ("quanta") of von Willebrand factor (vWF), the main WPB cargo.

265 xin downregulation inhibits the secretion of von Willebrand factor (VWF), the most abundant cargo in

266 During posttranslational modifications of von Willebrand factor (VWF), the VWF propeptide (VWFpp)

267 ADAMTS13 metalloprotease cleaves von Willebrand factor (VWF), thereby inhibiting platelet

268 et alpha-granules and their cargo, including von Willebrand factor (VWF), thrombospondin-1, and plate

269 275 patients with SIRS and plasma levels of von Willebrand factor (VWF), thrombospondin-1, myelopero

270 is prevented by the multidomain glycoprotein von Willebrand factor (VWF), which binds exposed collage

271 s is caused by the functional changes of the von Willebrand Factor (VWF), which mediates coagulation

272 However, von Willebrand factor (VWF), with help from our circulat

273 ytic anemia, associated with a deficiency in von Willebrand factor (VWF)-cleaving protease ADAMTS13.

274 ndin type 1 motif, member 13), also known as von Willebrand factor (VWF)-cleaving protease, as a prot

275 osis defect is not related to alterations in von Willebrand factor (VWF)-GPIb adhesive function or pl

276 l-protein tyrosine phosphatase (VE-PTP), and von Willebrand factor (vWf).

277 interaction between factor VIII (FVIII) and von Willebrand factor (VWF).

278 regulates the platelet-tethering function of von Willebrand factor (VWF).

279 orts initial platelet adhesion in absence of von Willebrand factor (VWF).

280 change in the platelet-binding A1 domain of von Willebrand factor (VWF).

281 with platelet adhesion, which is mediated by von Willebrand factor (VWF).

282 to blood vessels under shear stress requires von Willebrand factor (VWF).

283 ack of normal ADAMTS-13-mediated cleavage of von Willebrand factor (VWF).

284 ive pathologies of the adhesive glycoprotein von Willebrand factor (VWF).

285 isorder caused by decrease or dysfunction of von Willebrand factor (VWF).

286 critical for recognition and proteolysis of von Willebrand factor (VWF).

287 and circulates in a protective complex with von Willebrand factor (VWF).

288 injury requires both factor VIII (FVIII) and von Willebrand factor (VWF).

289 signed to have a higher binding affinity for von Willebrand factor (VWF).

290 esterol levels (HDL-C and LDL-C), and plasma von Willebrand factor (vWF).

291 ent therapy with desmopressin (DDAVP) and/or von Willebrand factor (VWF)/factor VIII concentrates.

292 he levels of amyloid-beta40, amyloid-beta42, von Willebrand factor (VWF; a measure of microvascular d

293 vator inhibitor type 1 [PAI-1], D-dimer, and von Willebrand factor [vWF]) were measured in plasma.

294 proximal promoter regions of most (eg, CD31, von Willebrand factor [vWF], VE-cadherin, and intercellu

295 By double immunostaining of Ki-67 and von Willebrand factor, we demonstrated that proliferatin

296 gen, type VI, alpha-3; thrombospondin 2; and von Willebrand factor) were verified by real-time polyme

297 low-serum medium showed robust secretion of von Willebrand factor when stimulated with various agoni

298 Angiopoietin-2 and von Willebrand factor, which are biomarkers of endotheli

299 ury by the acute release of the procoagulant von Willebrand factor, which is stored in unique secreto

300 ycoprotein Ib-IX-V with endothelial-released von Willebrand factor with a supporting role for the P-s